Aarti Drugs · NSE: AARTIDRUGS · BSE: 524348
Q2 FY21 results · Jul–Sep 2020
Aarti Drugs reported revenue from operations of ₹578.11 crore (up 21.1% from Q2 FY20) and net profit of ₹75.27 crore (up 133.0% from Q2 FY20) for Q2 FY21 (Jul–Sep 2020), on a consolidated basis.
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 578.11 | 477.50 | +21.1% | 544.67 | +6.1% |
| Other income | 0.29 | 0.19 | +52.6% | 1.26 | −77.0% |
| Total income | 578.40 | 477.69 | +21.1% | 545.93 | +5.9% |
| Profit before tax | 97.12 | 47.86 | +102.9% | 116.28 | −16.5% |
| Net profit for the period | 75.27 | 32.31 | +133.0% | 85.45 | −11.9% |
| EPS, basic (₹) | 32.30 | 13.87 | +132.9% | 36.67 | −11.9% |
| Net margin (%) | 13.0 | 6.8 | 15.7 |
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 515.16 | 442.71 | +16.4% | 475.55 | +8.3% |
| Other income | 0.26 | 0.21 | +23.8% | 1.24 | −79.0% |
| Total income | 515.42 | 442.92 | +16.4% | 476.79 | +8.1% |
| Profit before tax | 90.28 | 45.80 | +97.1% | 99.03 | −8.8% |
| Net profit for the period | 69.78 | 30.80 | +126.6% | 73.03 | −4.5% |
| EPS, basic (₹) | 29.95 | 13.22 | +126.6% | 31.34 | −4.4% |
| Net margin (%) | 13.5 | 7.0 | 15.4 |
Consolidated
- Filed with BSE
- 24 Oct 2020, 18:37 IST
- Board meeting
- 23 Oct 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 24 Oct 2020, 18:37 IST
- Board meeting
- 23 Oct 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Audited
- Source
- XBRL filing on BSE